Pharmabiz

AtaiBeckley doses last patient in Elumina, phase 2b trial of VLS-01 in adults with treatment-resistant depression

AtaiBeckley doses last patient in Elumina, phase 2b trial of VLS-01 in adults with treatment-resistant depression: New York Tuesday, July 7, 2026, 10:00 Hrs [IST] AtaiBeckley Inc.
BioProcess International

Cell- and Virus-Bank Characterization in Product Development: A Risk-Based, Phase-Appropriate Framework for Quality Control

Biopharmaceutical developers should introduce risk-based, phase-appropriate characterization strategies for quality control ...

AtaiBeckley Doses Last Patient in VLS-01 Phase 2b TRD Study; Plans Phase 3 in Major Depressive Disorder

Phase 2b Elumina trial; topline data anticipated in Q4 2026 (ClinicalTrials.gov: NCT06524830) AtaiBeckley plans to advance VLS-01 into major depressive disorder (MDD) in Phase 3, with generalized ...
Le Lézard

American Franchise Academy celebrates 10 years filling franchising's biggest gap -- Business Management

Ten years ago, a franchisee reached out for help. His business was failing, and he couldn't find guidance on how to save his dream. So, Aicha Bascaro ? a former pizza delivery driver turned global ...
Le Lézard

ePlus Appoints John Lutz to Board of Directors

Plus inc. today announced that John Lutz, a senior executive with more than 30 years' experience across global technology and institutional environments, has joined its Board of ...